Optimizing ATR inhibition and cisplatin synergy in Ewing sarcoma.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacological ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy.

Keyphrases

dna repair
dna damage response
low dose
dna damage
high dose
transcription factor
tyrosine kinase
stem cells
protein kinase
combination therapy
bone marrow
climate change